Synopsis
Synopsis
0
KDMF
0
VMF
0
FDA Orange Book
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Anaspaz
2. Atropine Sulfate, 3(s)-endo-isomer
3. Atropine, 3(s)-endo-isomer
4. Cytospaz
5. Hyoscyamine
6. Hyoscyamine Hydrobromide
7. Hyoscyamine Hydrochloride
8. Hyoscyamine Sulfate
9. Hyoscyamine Sulfate Anhydrous
1. Hyoscyamine Sulfate
2. Schembl34273
3. Chembl1697729
Molecular Weight | 387.4 g/mol |
---|---|
Molecular Formula | C17H25NO7S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 5 |
Exact Mass | 387.13517331 g/mol |
Monoisotopic Mass | 387.13517331 g/mol |
Topological Polar Surface Area | 133 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 434 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Adjuvants, Anesthesia
Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Bronchodilator Agents
Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Mydriatics
Agents that dilate the pupil. They may be either sympathomimetics or parasympatholytics. (See all compounds classified as Mydriatics.)
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
57
PharmaCompass offers a list of Hyoscyamine Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Hyoscyamine Sulfate manufacturer or Hyoscyamine Sulfate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Hyoscyamine Sulfate manufacturer or Hyoscyamine Sulfate supplier.
PharmaCompass also assists you with knowing the Hyoscyamine Sulfate API Price utilized in the formulation of products. Hyoscyamine Sulfate API Price is not always fixed or binding as the Hyoscyamine Sulfate Price is obtained through a variety of data sources. The Hyoscyamine Sulfate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Hyoscyamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Hyoscyamine, including repackagers and relabelers. The FDA regulates Hyoscyamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Hyoscyamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Hyoscyamine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Hyoscyamine supplier is an individual or a company that provides Hyoscyamine active pharmaceutical ingredient (API) or Hyoscyamine finished formulations upon request. The Hyoscyamine suppliers may include Hyoscyamine API manufacturers, exporters, distributors and traders.
click here to find a list of Hyoscyamine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Hyoscyamine DMF (Drug Master File) is a document detailing the whole manufacturing process of Hyoscyamine active pharmaceutical ingredient (API) in detail. Different forms of Hyoscyamine DMFs exist exist since differing nations have different regulations, such as Hyoscyamine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Hyoscyamine DMF submitted to regulatory agencies in the US is known as a USDMF. Hyoscyamine USDMF includes data on Hyoscyamine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Hyoscyamine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Hyoscyamine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Hyoscyamine Drug Master File in Japan (Hyoscyamine JDMF) empowers Hyoscyamine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Hyoscyamine JDMF during the approval evaluation for pharmaceutical products. At the time of Hyoscyamine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Hyoscyamine suppliers with JDMF on PharmaCompass.
A Hyoscyamine CEP of the European Pharmacopoeia monograph is often referred to as a Hyoscyamine Certificate of Suitability (COS). The purpose of a Hyoscyamine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Hyoscyamine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Hyoscyamine to their clients by showing that a Hyoscyamine CEP has been issued for it. The manufacturer submits a Hyoscyamine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Hyoscyamine CEP holder for the record. Additionally, the data presented in the Hyoscyamine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Hyoscyamine DMF.
A Hyoscyamine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Hyoscyamine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Hyoscyamine suppliers with CEP (COS) on PharmaCompass.
A Hyoscyamine written confirmation (Hyoscyamine WC) is an official document issued by a regulatory agency to a Hyoscyamine manufacturer, verifying that the manufacturing facility of a Hyoscyamine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Hyoscyamine APIs or Hyoscyamine finished pharmaceutical products to another nation, regulatory agencies frequently require a Hyoscyamine WC (written confirmation) as part of the regulatory process.
click here to find a list of Hyoscyamine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Hyoscyamine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Hyoscyamine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Hyoscyamine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Hyoscyamine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Hyoscyamine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Hyoscyamine suppliers with NDC on PharmaCompass.
Hyoscyamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Hyoscyamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Hyoscyamine GMP manufacturer or Hyoscyamine GMP API supplier for your needs.
A Hyoscyamine CoA (Certificate of Analysis) is a formal document that attests to Hyoscyamine's compliance with Hyoscyamine specifications and serves as a tool for batch-level quality control.
Hyoscyamine CoA mostly includes findings from lab analyses of a specific batch. For each Hyoscyamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Hyoscyamine may be tested according to a variety of international standards, such as European Pharmacopoeia (Hyoscyamine EP), Hyoscyamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Hyoscyamine USP).